

# **CANM ACMN**

**CANADIAN ASSOCIATION OF NUCLEAR MEDICINE  
*ASSOCIATION CANADIENNE DE MÉDECINE NUCLÉAIRE***

**2013 ANNUAL SCIENTIFIC MEETING  
RÉUNION SCIENTIFIQUE ANNUELLE 2013**

**FACULTY / CONFÉRENCIERS**

*Several Speakers' presentations will be available on the  
CANM Website after the conference.*

*Plusieurs présentations seront disponibles sur le  
site Web de l'ACMN après la conférence.*

**FACULTY LIST / LISTE DES CONFÉRENCIERS****Beaudoin, Gilles**

Gilles Beaudoin received his PhD in experimental high energy physics from the university of Montreal in 1990. For the first few years, he worked in detector development with the OPAL and ATLAS collaborations at CERN. Since 1996, he is at the Centre Hospitalier de l'Université de Montréal (CHUM), where he works in the imaging aspect of medical physics.

He is head of the master in medical physics program at the university of Montreal since 2002 and head of the Physics and biomedical engineering services at the CHUM since 2011.

His research interests are software and hardware development in MRI.

**Beaudry, Mélanie**

Dès l'obtention de mon diplôme en médecine nucléaire en 2005, j'ai commencé à travailler au CHUM et depuis plus de 2 ans, je suis la coordonnatrice technique du département de l'Hôtel-Dieu de Montréal. Ce dernier poste m'a permis de participer aux différents projets suivants :

1. Projet d'implantation d'une nouvelle plateforme de visualisation d'imagerie médicale
2. Projet d'uniformisation des protocoles techniques en médecine nucléaire sur les trois sites du CHUM conjointement avec l'équipe médicale
3. Participation à la planification des locaux et équipements pour le département de médecine nucléaire dans le Nouveau CHUM

À partir de 2007, j'ai débuté auprès de la compagnie Hermes Medical Solution contractuellement en tant que spécialiste d'application.

Latéralement à mes emplois, j'ai entrepris des études en gestion que je poursuis toujours. J'ai une implication au sein de mon organisation ainsi que de ma profession faisant partie du comité multidisciplinaire du CHUM et du comité inspection professionnelle de l'OTIMRO.

**Beauregard, Jean-Mathieu**

Dr. Jean-Mathieu Beauregard is a clinician-scientist in nuclear medicine, at the CHU de Québec, and Assistant Professor of Radiology at Université Laval in Quebec City, Canada. He was trained at Université de Sherbrooke, in Canada, and at the Peter MacCallum Cancer Centre in Melbourne, Australia.

Dr. Beauregard has a strong interest in molecular imaging and radionuclide therapy of neuroendocrine tumors. His research aims at developing personalized approaches to improve the efficacy of peptide receptor radionuclide therapy, including therapy planning with positron emission tomography and dosimetry methods based on quantitative single-photon emission computed tomography.

Jean-Mathieu Beauregard, M.D., M.Sc., FRCPC Professeur adjoint - Département de radiologie - Université Laval Spécialiste en médecine nucléaire - Département d'imagerie médicale - Centre hospitalier universitaire de Québec Chercheur - Axe cancer - Centre de recherche du CHUQ

**Blais, Marie-Claude**

Marie-Claude Blais is a pharmacist with over 20 years of experience in the pharmaceutical industry mainly in nuclear medicine drug product division. She has held several positions ranging from Regulatory Affairs Associate to Quality Operations in charge of implementing Quality Systems at several manufacturing sites of Schedule C and PERs drug products in Canada. She has been a visiting

professor at the Pharmacy Faculty of Montréal University and invited by Health Canada as a member of a working group developing the Good Manufacturing Practices (GMP) guidelines applicable to Positron Emitting Radiopharmaceuticals (PERs).

Marie-Claude Blais est pharmacienne avec plus de 20 années d'expérience dans l'industrie pharmaceutique principalement dans la division des produits radiopharmaceutiques. Elle a occupé différents postes allant des affaires gouvernementales à responsable de la mise en place d'un système de gestion de la qualité dans plusieurs établissements de fabrication des produits radiopharmaceutiques et d'émetteurs à positrons au Canada. Elle a été professeure invitée et chargée de cours à la *Faculté de pharmacie de l'université de Montréal*. Également, elle a aussi participé en tant que membre au groupe de travail chargé d'élaborer les directives sur les *Bonne pratiques de fabrication* (BPF) applicables aux produits radiopharmaceutiques émetteurs de positrons (PREP).

### **Bourassa-Moreau, Benoît**

Je suis physicien médical pour le département de médecine nucléaire des trois sites du CHUM depuis début 2012. J'ai complété cette même année une maîtrise en physique médicale à l'Université de Montréal que j'ai entrepris après mon baccalauréat en génie Physique à l'école Polytechnique de Montréal.

### **Bourguet, Patrick**

Dr. Bourguet est professeur en Biophysique et médecine nucléaire à l'Université de Rennes. Il a été président de la Société française de médecine nucléaire de 1999 à 2003 et est président de la Société européenne de médecine nucléaire (EANM) depuis 2011.

### **Driedger, Al**

Dr. Driedger was born in 1937 in Saskatchewan and received primary and secondary education near and in the town of Kindersley. After high school, he set up and ran a construction company for two years before he entered the University of Saskatchewan in 1956. Dr. Driedger graduated from the College of Medicine in 1963 and from Graduate Studies (PHD in Biochemistry) in 1967. After two years of post-doctoral fellowships at AECL and in England, he took a scientist position in Radiation Biology at AECL.

Eventually he began to seek a synthesis of the medical, biochemical and radiobiological threads of his experience and moved to UWO in 1970 to prepare himself for the practice of Nuclear Medicine. He has been on the UWO faculty since 1972. In 1976 the Royal College held the first examinations in Nuclear Medicine and he began to train specialists, an activity that provided great intellectual stimulation to students and faculty alike. Over the years, there were many opportunities for clinical research in pulmonary and cardiovascular physiology in the critically ill and in oncology and endocrinology. Dr. Driedger has 139 peer reviewed publications to his credit, 291 abstracts and he has given more than 218 lectures. Dr. Driedger retired from full time practice in 2007 but has continued to be active in some thyroid cancer and radiobiological issues.

Dr. Driedger is very grateful for the many opportunities he was given to serve the profession and to participate in the advancement of knowledge.

### **Gambhir, Sanjay**

Presently, holding position of Head of Nuclear Medicine, at Sanjay Gandhi post-Graduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, Professor Sanjay Gambhir has obtained the medical degree of MBBS from Maulana Azad Medical College, Delhi University in 1985 and post-graduate training in Nuclear Medicine from Institute of Nuclear Medicine, Delhi University with Board

certification in Nuclear Medicine from National Board, New Delhi. After undergoing residency training Dr. Sanjay Gambhir has been working as faculty and Head of Nuclear Medicine at SGPGIMS, Lucknow. Sanjay Gandhi post graduate institute is a reputed multi-specialty teaching and training hospital in governmental sector with mandate to start new teaching and training courses and absorb new technology. This institute has to its credit the first 3-year didactic post-graduate teaching and training course in Nuclear Medicine in India, which has been replicated by other leading teaching hospitals in India. Residents from this institute are manning many Nuclear medicine centres in India.

With good international exposure of collaborative work and spending time in Japan, England and Canada through various exchange programmes, Dr. Gambhir has good understanding of newer technologies in the field of Nuclear Medicine and its adaptation for growing economy like India with special interest in hybrid imaging.

With keen interest in policy making and growth of this specialty in India, Prof. Gambhir has been Past President of the Society of Nuclear Medicine, India and Nuclear Cardiological Society of India. Dr. Gambhir is advisor to Medical Council of India and the National Board of Certification for the specialty of Nuclear Medicine.

### **François Hébert**

Diplômé du Collège Ahuntsic en 1995, François Hébert a occupé successivement plusieurs fonctions au sein du CHUM de 1997 jusqu'en 2008 alors comme gestionnaire à titre de Chef-Technologue au Département de médecine nucléaire. Parallèlement, il a également agi à titre de Professeur clinique au Collège Ahuntsic ainsi qu'en tant que formateur-consultant pour la radio-immunothérapie Bexxar™. Depuis la fin 2008, M. Hébert s'est joint à la compagnie HERMES Solutions Médicales Canada d'abord comme Spécialiste de Produits et depuis juin 2012 en tant que Directeur des Ventes.

### **Juneau, Daniel**

Dr. Juneau a gradué de la faculté de médecine de l'Université de Montréal en 2009. Il est actuellement résident de quatrième année dans le programme de médecine nucléaire de l'Université de Montréal. Il est très impliqué dans le programme, participant entre autre au comité pédagogique depuis maintenant 2 ans, et est résident coordonnateur du programme depuis 2011.

Dr Juneau possède également un intérêt pour l'éthique clinique et est membre du comité d'éthique clinique du CHUM et consultant en éthique clinique.

### **Klein, Agnes**

Agnes V. Klein MD, DPH, is currently the Director, Centre for the Evaluation of Radiopharmaceuticals and Biotherapeutic Products in the Biologics and Genetic Therapies Directorate.

After receiving her medical degree from the University of Toronto, Dr. Klein trained in Endocrinology, Medical Biochemistry and Public and Community Health. After joining Health Canada, she has occupied many and varied positions, scientific and managerial. Amongst relevant accomplishments, Dr. Klein represented Health Canada on NCBHR, as founding member and NCEHR as well as chairing the Committee on Clinical Trials of the Council. Dr. Klein's chosen career was to be in academic medicine and clinical research and her interests in biomedical ethics and the development of therapies started early on, before the age of 10.

In 2000, Dr. Klein moved from the Drugs side of the regulatory Directorates to Biologics and was at the forefront of many of the changes that shaped the current Biologics and Genetic Therapies Directorate.

Dr. Klein was an active participant in the CIOMS document on Pharmacogenetics and Pharmacoeconomics. She is also actively participating in the ICH process (ICH E15 and E16 related to pharmacogenomics) and, most recently, was the champion of a new Pharmacogenomics Regulatory Guideline issued by Health Canada.

Dr. Klein's special interests include biomarkers, surrogate endpoints and the appropriate design of clinical trials and the various and complex design, analysis and ethical issues attendant to them. Dr. Klein has also a special interest in newer clinical trial designs for small studies. Dr. Klein is a member of Health Canada's Research Ethics Board and an active member of several medical and scientific organizations nationally and internationally.

Dr. Klein has made numerous presentations to professional and regulatory groups on issues surrounding the ethics of clinical trials and the integrity of clinical trial data. Dr. Klein has also presented on a wide-variety of new regulatory endeavours.

Dr. Klein is involved actively with the various meetings organized through the Drug Information Association since 1985.

Dr. Klein is an active supporter for excellence in the development of medicines.

### **Laforce, Robert**

Dr. Robert Laforce served as Maritime Surface Officer, Naval Reserve, Canadian Armed Forces from 1987-1994. He obtained his PhD in Clinical Neuropsychology from Laval University with his internship at the Ottawa General Hospital. From 1998-2002 Dr. Laforce was assistant professor of Neuropsychology at the University of New Brunswick. He obtained his MD from Laval University in 2006. From 2006-2011 he did his Neurology Residency at l'hôpital l'Enfant-Jésus in Québec City. He did a Fellowship in Behavioural Neurology at UC San Francisco (Dr. Bruce Miller) and Amyloid Imaging at UC Berkeley (Dr. Gil Rabinovici). In 2012, Dr. Laforce is Assistant Professor of Behavioural Neurology, Faculty of Medicine at Laval University.

### **Leblond, Antoine**

Dr. Antoine Leblond trained in nuclear medicine at the University of Montreal from 2002 to 2007. He then pursued his formation in PET/CT at the University of Washington Medical Center in Seattle (2007-2008).

Following his fellowship, he worked there for an additional two years as a physician and assistant professor. He was also Assistant Program Director for Nuclear Medicine at the University of Washington from

2008 to 2010. He came back to Montreal in July 2010 to work at the Centre Hospitalier de l'Université de Montréal (CHUM). Dr Leblond is the Program Director for Nuclear Medicine at the University of Montréal since October 2011. He is clinical assistant professor at the University of Montreal (Department of Radiology, Radio-Oncology and Nuclear Medicine). Dr Leblond is involved at many levels in his clinical and academic institutions. He has marked interest in Information Technologies.

### **Lord, Martin**

Dr. Lord a obtenu son certificat de spécialiste en médecine nucléaire du Collège Royal des médecins et chirurgiens du Canada en 2003. Il a ensuite travaillé pendant six ans, de 2003 à 2009, comme nucléiste à l'Hôtel-Dieu de St-Jérôme et a été chef du département de médecine nucléaire entre 2006 et 2009.

Au début de l'année 2009, il a décidé de se joindre à l'équipe de médecine nucléaire de l'hôpital Maisonneuve-Rosemont de Montréal, en raison de l'installation récente d'une TEP/TDM. Sa pratique médicale consista dès lors à plus de 90% d'oncologie.

Dans le but ensuite de vivre une expérience de travail au niveau international, il s'est joint au service de médecine nucléaire de Genève, en Suisse, en août 2010, en tant que chef de clinique et a eu la chance de travailler avec une toute nouvelle technologie, la TEP/IRM. Il a plus particulièrement pris en charge les examens TEP/IRM à la fluorocholine pour les cancers de la prostate et les examens pédiatriques.

Depuis décembre 2011, il est de retour comme professeur adjoint au Centre hospitalier de l'Université de Montréal et est responsable de l'évaluation en médecine nucléaire à l'Hôtel-Dieu de Montréal.

### **Normandeau, Lysanne**

Diplômée de biophysique de l'Université de Montréal, a poursuivi des études graduées en Health Physics à l'Université d'Oak Ridge au Tennessee.

Physicienne en radioprotection d'abord à l'Université de Montréal puis comme consultante.

Physicienne responsable de radioprotection dans le milieu médical d'abord à l'Hôpital général de Montréal puis au CHUM depuis 14 ans.

Professeur de radioprotection au programme de maîtrise en physique médicale de l'U de M et chargée d'enseignement clinique au CHUM.

Membre du Comité aviseur de radioprotection de la CCSN durant sept ans.

### **Rahmanie, Slimane**

Slimane Rahmani, M.Sc.A. a obtenu le diplôme d'ingénieur en électronique, option instrumentation, à l'Université de Sétif. Il a ensuite obtenu une maîtrise en microélectronique à l'Université de Constantine. Peu après son arrivée au Canada, il a débuté une maîtrise en génie clinique, un programme conjointement donné par l'École polytechnique de Montréal et l'université de Montréal. Durant la même période, il a complété les examens lui permettant de devenir membre des ingénieurs du Québec.

En 2002, Slimane Rahmani a occupé le poste d'ingénieur biomédical au Centre hospitalier de l'université de Montréal (CHUM) où il a œuvré à la gestion des opérations des systèmes PACS. En même temps, il a dirigé la réorganisation des systèmes de gestion de l'imagerie nucléaire, dont le département comptait près de 20 caméras et un TEP. En 2005, il est devenu le principal responsable du système PACS au CHUM. Il a participé à plusieurs projets d'envergures, notamment le déploiement d'un PACS multi-sites, l'évolution du PACS vers d'autres secteurs producteurs d'images comme la gastroentérologie, l'échocardiographie, l'hémodynamique, etc.

En 2008, Slimane Rahmani a complété une spécialisation en physique médicale, un programme donnée par le département de physique de l'université de Montréal. En plus de piloter les projets informatiques biomédicaux, il a assuré la gestion, le maintien et le développement des équipements d'angiographie du CHUM. Durant la même période, il est devenu co-gestionnaire d'une entreprise privée qui offre des services de consultation et d'inspection des équipements à rayons-X « Connectimage Medical Inc. ».

Aujourd'hui, Slimane Rahmani est responsable des systèmes de mammographie du centre de référence pour investigation désignés du CHUM et des systèmes d'information clinique relevant du service de physique et génie biomédicale du CHUM. Il est impliqué dans divers programmes d'enseignement de l'imagerie médicale notamment celui dispensé par le département de physique médicale, celui de la faculté de médecine et enfin, celui de l'école polytechnique. Il est auteur de multiples communications scientifiques portant sur les PACS. Il prépare une Maîtrise en administration des affaires (MBA) à l'université du Québec à Montréal. Son achèvement est prévu pour décembre 2013.

### **Rajaraman, Mal**

After completing residency at Dalhousie and a Fellowship at the Princess Margaret Hospital in Toronto, Dr. Murali (Mal) Rajaraman has been a Radiation Oncologist in the Department of Radiation Oncology, Dalhousie University and Capital District Health Authority, Nova Scotia Cancer Centre. He is a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC) and a Diplomate of the American Board of Radiology in Radiation Oncology.

Dr. Rajaraman's clinical expertise is in the areas of Thyroid Cancer, Head & Neck Cancer, Sarcoma, Lung Cancer, and Skin Cancer. Research activities and interests are in the fields of Neosis, Clinical and Research Databases, Thyroid Cancer Care, PET/CT scan utilization in Oncology and Clinical Trials. Administrative and academic responsibilities have included Membership of the NCIC-CTG Canadian Sarcoma Group Executive Committee, CARO Manpower and Standards Committee, CARO Elekta Research Fellowship Program Selection Committee, Thyroid Cancer Canada Medical Advisory Panel, and Chairmanships of the Cancer Care Nova Scotia Cancer Site Teams in Head and Neck Cancer and Sarcoma (Musculoskeletal Cancer).

### **Rayson, Daniel**

Dr. Daniel Rayson is a Medical Oncologist at the Queen Elizabeth II Health Sciences Centre, as well as Professor of Medicine and Pediatrics at Dalhousie University. He completed his medical training at Dalhousie University and went on to specialize in Internal Medicine and Hematology/Medical Oncology at the Mayo Clinic in Rochester, Minnesota. His main areas of clinical care and research are in breast and gastrointestinal neuroendocrine oncology, with major areas of interest in cancer genetics, clinical trial development, as well as health services and translational research. He is past Chair of the Nova Scotia Provincial Breast Cancer Site Team (2000-2009) and the Clinical Trial Grant Panel Review Committee of the National Cancer Institute of Canada (2006-2009). In February 2008, he was appointed as Director of the Atlantic Clinical Cancer Research Unit (ACCRU) at the Queen Elizabeth II Health Sciences Centre and is a founding board member of the Beatrice Hunter Cancer Research Institute (BHCRI).

### **Root, John**

Dr. John Root received his PhD in physics, from the University of Guelph in 1986. He joined Atomic Energy of Canada Limited (AECL), where he developed a method to map stresses inside materials with neutron beams. This method is now applied worldwide to help industries improve their products, and expand their businesses. Dr. Root was appointed as Director of the NRC's "Canadian Neutron Beam Centre" in 2003. This user facility welcomes researchers and students from universities, industries and government laboratories from across Canada and from abroad. By accessing the specialized neutron-beam facilities and expertise at the Centre, users advance their knowledge of materials at the molecular and nano-scale, for applications such as transportation safety, manufacturing competitiveness, lifetime management of infrastructure, market development, fundamental scientific understanding and education.

During the past year, Dr. Root has established the Sylvia Fedoruk Canadian Centre for Nuclear Innovation Inc, whose purpose is to place Saskatchewan among global leaders of nuclear research, development and innovation, through investment in partnerships with academia and industry. The Centre was incorporated as a wholly owned, not-for-profit subsidiary of the University of Saskatchewan on December 20, 2011.

### **Rosa-Neto, Pedro**

Dr. Pedro Rosa-Neto MD (Federal University Rio Grande do Sul, Brazil) PhD (Aarhus University PET Centre, Denmark) is an assistant professor of Neurology, Neurosurgery and Psychiatry at McGill University, affiliated to the Douglas Research Centre. He is a clinical neurologist with expertise in quantification of brain function using imaging techniques, in particular Positron Emission Tomography (PET). Dr. Rosa-Neto's research interests focus on imaging biomarkers for neurodegenerative diseases. He directs the laboratory for translational neuroimaging, which aims to use imaging techniques to advance the diagnosis of Alzheimer's disease to a preclinical stage. Dr. Rosa-Neto research is funded by Alzheimer's Association USA (Alzheimer's Association Young Investigator), Canadian Foundation for

innervation (CFI) , Fonds de la Recherche en Santé du Québec (FRSQ), Canadian Institutes of Health Research (CIHR) and Nussia & André Aisenstadt Foundation.

### **Ross, Andrew**

Dr. Andrew Ross was born and raised in the Maritimes. He did his undergraduate studies, Medicine and Radiology at Dalhousie University in Halifax. He graduated in Medicine in 1987, finished his Radiology residency in 1993, did his Nuclear Medicine residency at UBC and finished in 1994, and did a PET fellowship in Melbourne Australia with Dr. Rod Hicks in 2007. Dr. Ross is currently Division Head of Nuclear Medicine in Capital District Health Authority in Halifax and Associate Professor at Dalhousie University; he is also Medical Director of the Nova Scotia PET Center.

### **Sha, Girish**

Dr. Girish Shah is Full Professor of the Faculty of Medicine at Laval University. He is also Head of the Laboratory for Skin Cancer Research at the CHUL (CHUQ) Hospital Research Centre of Laval University since 1997. Dr. Shah's research is focused on carcinoid neuroendocrine tumors (NET) and solar ultraviolet radiation-induced skin cancers with specific emphasis on DNA damage, DNA repair and cell death processes, which can influence either the development of these cancers or their resistance to therapy.

The incidence of NET has been increasing in the past decade without major improvement in survival. While surgery is the only curative option, conventional medical therapies including chemotherapy have shown limited efficacy for the inoperable/metastatic disease, and cure is rare. Dr. Shah's team, earlier reported that nearly ¼ of the carcinoid-NET patients suffer from subclinical niacin (vitamin B3) deficiency, an incidence that is much higher than pellagra, the clinical niacin deficiency syndrome reported in these patients. More recently, his team has been using cellular and nude mouse models of carcinoid NET to examine various therapeutic options.

Dr. Shah has received an award for the "Outstanding Achievement in Carcinoid/Neuroendocrine Tumor Research" in 2006 from the Carcinoid Cancer Foundation Inc. USA. Dr. Shah has also been a recipient of the Research Scholar awards from the Quebec Health Research Fund (FRSQ). Dr. Shah's research on carcinoid cancer is currently supported by Canadian Institutes of Health Research, and was supported in the past by the Cancer Research Society Inc. of Canada and the Carcinoid Cancer Foundation of USA.

### **Soucy, Jean-Paul**

Dr. Jean-Paul Soucy is Assistant Professor in the Department of Diagnostic Radiology of McGill University and Coordinator of the Positron Emission Tomography (PET) Unit in the McConnell Brain Imaging Centre at the Montreal Neurological Institute. He also is a full professor (clinical) in the Department of Radiology, Faculty of Medicine, Université de Montréal.

Dr. Soucy received his Medical Degree (M.D.), and was first in his class, at the Université de Montréal's School of Medicine (1980). He conducted his residencies from 1980-1984 with the Université de Montréal and McGill University. Dr. Soucy also received a Masters Degree (M.Sc) in Neuroscience (1993) from the Université de Montréal. He received a C.S.P.Q. Nuclear Medicine (Specialty Certification of the Quebec College of Physicians) in 1984, F.R.C.P.(c) Nuclear Medicine in 1984, a D.E.S. (Specialty Diploma, Nuclear Medicine) from the Université de Montréal, as well as Board Certification, American Board of Nuclear Medicine, in 1984. He was a Post graduate Fellow of the McLaughlin Foundation at service hospitalier Frédéric Joliot, France in 1985.

Dr.Soucy has given over 200 presentations at scientific meetings world-wide, and has been invited to speak at over 70 conferences across Canada, in Brazil and the US. He is or has been a member of a variety of committees including Surveyor for the Royal College of Physicians and Surgeons of Canada since 2000, and Executive Committee Member of the Canadian Association of Nuclear Medicine. He



currently is Chair of the Conjoint Committee on Accreditation of the CMA. He is a member of a number of societies including, the Society of Nuclear Medicine, Society for Neuroscience, the Organization for Human Brain Mapping and is a founding member of the Society for Fronto-temporal Dementias.

He has published approximately over 100 abstracts in respected scientific journals, 7 book chapters, and over 50 papers in peer-reviewed journals. He has tutored and supervised medical residents and post-grad students from around the world. His research interests are in the field of cerebral blood flow quantification and image restoration with SPECT, as well as *in vivo* acetylcholine imaging in dementia and other neurodegenerative diseases using PET.

Dr Soucy has received many accolades throughout his career, in addition to those for excellence in academic performance, he is the recipient of a prestigious teaching award in two consecutive years, the Prix Esculape – Best teacher in Nuclear Medicine 1991-92, and 1992-93 from hôpital Notre-Dame.

### **Taillefer, Raymond**

Raymond Taillefer M.D. is a specialist in nuclear medicine, board certified in Québec, Canada and United States . He is a fellow of the Royal College of Physicians and Surgeons of Canada, and certified by the American Board of Nuclear Medicine and by the Council of Nuclear Cardiology. He is a Professor of Nuclear Medicine at the Department of Radiology of the University of Montreal. He is also the Director of the Departement of Nuclear Medicine at the Centre Hospitalier du Haut-Richelieu. Dr Taillefer's 30 year of clinical research has led to more than one hundred peer-reviewed original scientific manuscripts, more than 950 lectures and 175 published abstracts, and more than 30 books and book chapters. He is serving as an editorial board member of several scientific medical journals including the Journal of Nuclear Medicine, the Journal of Nuclear Cardiology, and Clinical Nuclear Medicine. Dr Taillefer has received national and international awards for his contributions in the field of nuclear medicine, including the Herman L.B. Blumgart Award for his pioneering work in cardiovascular radionuclide imaging and services to the Cardiovascular Council of the Society of Nuclear Medicine, and the Jean.A.Vezina Award given by the Société Canadienne-Francaise de Radiologie , acknowledging his unique contribution, innovation and excellence to the field of nuclear medicine. Dr Taillefer has been selected by his peers to be listed as one of the Best Doctors in America (published by Woodward/White) and one of the Best Doctors in Canada.

### **Tanguay, Yves**

Obtenu mon diplôme de technologue en médecine nucléaire du collège Ahuntsic à Montréal en 1977. J'ai travaillé dans différents hôpitaux à titre de Technologue en médecine nucléaire jusqu'en 1986, notamment au centre hospitalier de Verdun.

Enseigne en Technologie de médecine nucléaire au Collège Ahuntsic depuis 1986.

J'ai présenté plusieurs conférences au cours des années à plusieurs congrès de l'AMSMNQ.

### **Turgeon, Jacques**

Since spring 2007, Dr. Jacques Turgeon has been appointed Director of Research at the Centre hospitalier de l'université de Montréal. From 2005-2007 he was Vice-Rector – Research. Université de Montréal and from 2000-2005, he has served as Dean of the Faculté de pharmacie, Université de Montréal. He received his Bachelor degree in pharmacokinetics and a Ph.D. degree in drug metabolism from the same institution in 1985 and 1988, respectively. He completed post-doctoral studies from 1988 to 1990 in the department of Clinical Pharmacology, Vanderbilt University in Nashville, USA, under the supervision of Dr. Dan M. Roden. He joined the Faculty of Pharmacy of Laval University in 1990 as an assistant professor. He was promoted to the rank of associate professor in 1993 and full professor in 1998. From March 1999 to May 2000, he was Senior Director of the Pharmacokinetics department at Phoenix International Life Sciences.

Research interests of Dr. Turgeon have always been directed towards the study of factors responsible for intersubject variability in drug response. More specifically, he has developed expertise in the role of pharmacogenetics in cardiovascular drug actions. Among his favourite topics is the study of drug-drug interactions leading to pharmacodynamics modulation of antiarrhythmic drug action. Dr. Turgeon has integrated in his research approaches *in vitro* (patch-clamp technique *in vitro* metabolism and molecular biology) models as well as designed and performed studies in healthy volunteers and patients. Dr. Turgeon is recognized internationally for his work on CYP450s and mechanisms of drug-drug interactions. He has published more than 100 referred articles and more than 300 abstracts. Dr. Turgeon has received numerous prizes for his research activities as well as recognition by the students for his teaching skills. He is a member of numerous societies and has been acting on the committees of several granting agencies for several years. He has been the Director of Québec Cardiovascular Network of the FRSQ and the Research Director of the Québec Heart Institute, Laval Hospital.

*Depuis le printemps 2007, le Docteur Jacques Turgeon est directeur de la recherche au Centre hospitalier de l'Université de Montréal. De 2005 à 2007, il a été vice-recteur à la recherche de l'Université de Montréal et de 2000 à 2005 il a occupé le poste de doyen de la Faculté de pharmacie à cette même université. Auparavant, il occupait le poste de Directeur senior du Département de pharmacocinétique chez Phoenix International Sciences de la Vie à Montréal. Il a reçu un baccalauréat en pharmacie de l'Université de Laval en 1983, suivi d'un diplôme de M.Sc. en pharmacocinétique et d'un Ph.D. en métabolisme des médicaments de la même institution en 1984 et 1987 respectivement. Il a complété sa formation par des études postdoctorales de 1988 à 1990 au Department of Clinical Pharmacology, Vanderbilt University à Nashville aux États-Unis. Il s'est joint à la Faculté de pharmacie de l'Université Laval en 1990; à titre de professeur adjoint. Il fut promu au rang de professeur agrégé en 1993 et au rang de professeur titulaire en 1998.*

*Les intérêts de recherche du Dr Turgeon ont toujours été orientés vers la découverte de la caractérisation de facteurs pouvant expliquer la variabilité individuelle dans la réponse aux médicaments. De façon un peu plus spécifique, il s'intéresse au rôle de facteurs génétiques dans la réponse aux agents cardio-vasculaires. Parmi ses thèmes favoris, on retrouve l'étude d'interactions médicamenteuses chez des gens présentant des polymorphismes au niveau des cytochromes P450. Au cours des dernières années, le Dr Turgeon a su intégrer des approches de recherche novatrice de la cellule à l'homme. Il a présentement à son actif une centaine de publications et plus de 245 résumés de conférence. Le Dr Turgeon a reçu de nombreux prix et distinctions tant pour la qualité de son enseignement et la qualité de sa recherche. Il a servi sur plusieurs comités d'organismes subventionnaires et à titre de responsable de la recherche à l'institut de cardiologie de l'Hôpital Laval à Ste-Foy.*

### **Urbain, Jean-Luc**

Jean-Luc Urbain is Chief Medical Imaging at the Lebanon VA Medical Center. He is also deputy ACOS. Dr. Urbain has been an active member of the Medical Imaging community for more than 25 years. Originally a native from Belgium, he earned his Medical Degree at the Catholic University of Louvain in Europe. He pursued training in Internal Medicine and Nuclear Medicine and is board certified in Medicine and Nuclear Medicine. He also has a Ph.D. in Genetics and Molecular Biology.

Dr. Urbain has held medical leadership positions at Fox Chase Cancer Center, in Philadelphia, the Cleveland Clinic and the University of Western Ontario, in Canada. He is a member of numerous professional medical organizations and a Director of The Carcinoid Neuro-Endocrine Tumor Society, a patient Advocacy Organization. Evidence Based, Molecular and Personalized Medicine are his current areas of interest.

## **Wei, He**

## **Wells, Glenn**

Dr. Glenn Wells is an Associate Professor of Medicine (Cardiology) at the University of Ottawa Heart Institute and an Adjunct Professor of Physics at Carleton University. He received his PhD in medical physics (SPECT Imaging) in 1997 from the University of British Columbia. He pursued post-doctoral research in SPECT imaging at the University of Massachusetts Medical Center in Worcester, MA, USA until 2000 when he returned to Canada to take a position as a medical physicist with St. Joseph's Hospital and the Lawson Health Research Institute in London, ON. In 2006, he relocated to Ottawa, to join the Nuclear Cardiology department at the University of Ottawa Heart Institute.

Dr. Wells' research interests are in the physics of multi-modality imaging with nuclear medicine: the combination of multi-slice X-ray computed tomography (CT) with single-photon emission computed tomography (SPECT) and positron emission tomography (PET). More specifically, he is interested in the modification of reconstruction algorithms to more accurately correct for attenuation, scatter, camera resolution, and physiological motion. He is applying this research in the fields of dedicated cardiac clinical SPECT and SPECT/CT. His research is funded by Natural Sciences and Engineering Research Council of Canada, the Heart and Stroke Foundation of Ontario and the Ontario Ministry of Research and Innovation.

## **Zuckier, Lionel**

Dr. Lionel Zuckier is the recently installed Division Chief and Chair of Nuclear Medicine at The Ottawa Hospital. Prior to his arrival in Ottawa he most recently served as Professor of Radiology at the University of Pennsylvania and was Section Chief of Nuclear Medicine at the affiliated V.A. Hospital. He holds boards in the American Board of Nuclear Medicine, the American Board of Radiology, and the Certification Board of Nuclear Cardiology and was certified as a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC) in Nuclear Medicine in 1986.

